Journals / Journal of Clinical and Analytical Medicine / 2015 / Cilt: 6 - Sayı: 6

Clinicopathologic Prognostic Factors in Locally Advanced Pancreatic Cancer Patients Treated with Radiation Therapy

Radyoterapi ile Tedavi Edilen Lokal İleri Evre Pankreas Kanserinde Klinikopatolojik Prognostik Faktörler

Pages
707–711
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Tartışma: Pankreas kanseri nedeniyle radyoterapi alması planlanan hastalarda tümör çapı ve lenf nodu durumu prognostik faktörler olarak dikkate alınmalıdır.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Giriş: Pankreas kanseri prognozu en kötü malignitelerdendir.
📊
Key Findings & Data:Çalışmamızda kliniğimizde lokal ileri pankreas kanseri nedeniyle adjuvan ve definitif radyoterapi (RT) uygulanan hastalar değerlendirilmiştir.
💡
Conclusion & Impact:Tartışma: Pankreas kanseri nedeniyle radyoterapi alması planlanan hastalarda tümör çapı ve lenf nodu durumu prognostik faktörler olarak dikkate alınmalıdır.
🔬Design:Research Article
📍Scope:2000-2008 · 32 hasta
⚙️Variables:Domain Parameters

Abstract

Giriş: Pankreas kanseri prognozu en kötü malignitelerdendir. Son zamanlarda yapılan randomize klinik çalışmalarda adjuvan kemoterapi (KT), adjuvan kemoradyoterapi veya sadece cerrahi sorularına yanıt aranmaktadır. Çalışmamızda kliniğimizde lokal ileri pankreas kanseri nedeniyle adjuvan ve definitif radyoterapi (RT) uygulanan hastalar değerlendirilmiştir. Gereç ve Yöntem: 2000-2008 yılları arasında Akdeniz Üniversitesi Radyasyon Onkolojisi Ana Bilim Dalı'nda takip edilen histopatolojik olarak tanısı doğrulanmış ve görüntüleme yöntemleri ile evrelendirme çalışmaları yapılmış pankreas kanserli hastalar retrospektif olarak değerlendirildi. Bulgular: Çalışmaya toplam 32 hasta alındı. Tümör çapına göre sağkalımı belirlemede ROC (Receiver Operating Characteristics) analizi kullanıldı. Hastalar tümor çaplarına göre Grup A, tm çapı 4 cm'den küçük, Grup B tm çapı 4 cm'den büyük olarak gruplara ayrıldı. Hastalarda ortalama sağkalım; 17.3 ay idi. Lenf nodu tutulumu olup olmamasının sağkalımla ilişkisi yoktu (p=0.009). Sağkalım açısından Grup A ve B arasında anlamlı fark vardı. (p=0.029). Tartışma: Pankreas kanseri nedeniyle radyoterapi alması planlanan hastalarda tümör çapı ve lenf nodu durumu prognostik faktörler olarak dikkate alınmalıdır.

Özet

Aim: The prognosis of pancreatic cancer is one of the worst malignancies. In randomized clinical trials done in recent times, the answer is researched for adjuvant chemotherapy, chemoradiotherapy. Our study investigated the clinicopathologic prognostic factors for pancreatic cancer. Material and Method: Patients diagnosed with histopathologically confirmed pancreatic cancer, followed by Akdeniz University School of Medicine, Department of Radiation Oncology between the years 2000-2008 were included in the study. Results: A total number of 32 patients were taken to the study. The tumor diameter values in predicting survival were analyzed using ROC (Receiver Operating Characteristics) curve analysis. Patients were grouped according to their tumor diameters: the tumor diameter lower than 4 cm (Group A), the tumor diameter higher than 4 cm (Group B). The mean survival of patients is determined as 17.3 months. The fact that there is whether or not lymph node involvement is found to be related with survival (p=0.009). A significant relationship between Group A and B in terms of survival is determined (p=0.029). Conclusions: While treatment is considered in patients who are planned to receive radiation therapy because of pancreatic cancer, the tumor diameter and the lymph node status should be taken into account as prognostic factors.

🔖

Cite This Article

AKSU, G., KORCUM, A. F., YILDIRIM, M., YAVUZ, A. A., KAYA, V., ÖZDEMİR, B. Ş. (2022). Clinicopathologic Prognostic Factors in Locally Advanced Pancreatic Cancer Patients Treated with Radiation Therapy. Journal of Clinical and Analytical Medicine, Cilt: 6 - Sayı: 6, 707–711. https://ajindex.com/articles/560941

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013;144(6):1252-61
  2. Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010;28(2):355-8
  3. LiD, Xie K,Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363(9414):1049- 57
  4. Shimoike N, Fujikawa T, Maekawa H, Tanaka A. Aggressive secondary surgery for local recurrence of pancreatic cancer. BMJ Case Rep 2013; DOI: 10.1136/bcr. 009914
  5. Savir G, Huber KE, Saif MW. Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP 2013;14(4):337-9
  6. Choti MA. Adjuvant therapy for pancreatic cancer--the debate continues. N Engl J Med 2004;350(12):1249-51
  7. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg 2006;244(2):332-3
  8. Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009;27(17):2855- 62
  9. Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996;223(2):147-53
  10. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165(1):68-72
  11. Pongprasobchai S, Pannala R, Smyrk TC, Bamlet W, Pitchumoni S, Ougolkov A, et al. Long-term survival and prognostic indicators in small ( 12. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165(1):68-72
  12. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003;237(1):74-85
  13. Picozzi VJ, Abrams RA, Decker PA, Traverso W, O’Reilly EM, Greeno E, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011;22(2):348-54
  14. Michael R. Horsman, Bradly G. Wouters, Michael C. Joiner, Jens Overgaard. The oxygen effect and fractionated radiotherapy. In: Michael Joiner, Albert van der Kogel, editors. Basic Clinical Radiobiology. 4th ed. London: Hodder Arnold Press; 2009. p. 212-3
  15. Tsunoda T, Yamamoto Y, Kimoto M, Imai H, Iwamoto S, Kawasaki S, et al. Staging and treatment for pati